Mostrar el registro sencillo del ítem
dc.contributor.author | Vermeiren, Marie R. | |
dc.contributor.author | Calandri, Ismael Luis | |
dc.contributor.author | van der Flier, Wiesje M. | |
dc.contributor.author | van de Giessen, Elsmarieke | |
dc.contributor.author | Ossenkoppele, Rik | |
dc.date.accessioned | 2024-12-10T15:45:06Z | |
dc.date.available | 2024-12-10T15:45:06Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | Vermeiren MR, Calandri IL, van der Flier WM, van de Giessen E, Ossenkoppele R. Survey among experts on the future role of tau-PET in clinical practice and trials. Alzheimers Dement (Amst). 2024 Nov 22;16(4):e70033. doi: 10.1002/dad2.70033. | es_ES |
dc.identifier.uri | https://doi.org/10.1002/dad2.70033 | |
dc.identifier.uri | https://repositorio.fleni.org.ar/xmlui/handle/123456789/1300 | |
dc.description.abstract | Background: Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau-PET) in the future. Methods: We conducted an online survey among dementia and PET experts worldwide to investigate the anticipated future role of tau-PET in clinical practice and trials. Results: Two hundred sixty-eight dementia experts, comprising 143 clinicians and 121 researchers, covering six continents participated. The vast majority (90%) fostered a positive attitude toward the added value of tau-PET in clinical practice, particularly for staging, diagnosing, monitoring, and prognostication in a cognitively impaired memory clinic population. Experts anticipated an important role for tau-PET for participant selection (76%-100%) and measuring endpoints (75%-97%), in both anti-amyloid and anti-tau drug trials. Discussion: Our global survey study shows that dementia experts envision an important role for tau-PET in the future, both in clinical practice and in drug trials, beyond current guidelines and practices. Highlights: Dementia experts envision an important role for tau-PET in the future.Experts indicate that a tau-PET scan could influence patient management.Experts anticipate the utility of tau-PET for participant selection and endpoints in drug trials.There is a gap between the anticipated usefulness of tau-PET and current clinical practices. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley on behalf of the Alzheimer's Association | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Proteínas tau | es_ES |
dc.subject | tau Proteins | es_ES |
dc.subject | Tomografía de Emisión de Positrones | es_ES |
dc.subject | Positron-Emission Tomography | es_ES |
dc.subject | Alzheimer Disease | es_ES |
dc.subject | Enfermedad de Alzheimer | es_ES |
dc.title | Survey among experts on the future role of tau-PET in clinical practice and trials | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.description.fil | Fil: Calandri, Ismael Luis. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina. | |
dc.relation.ispartofVOLUME | 16 | |
dc.relation.ispartofNUMBER | 4 | |
dc.relation.ispartofPAGINATION | e70033 | |
dc.relation.ispartofCOUNTRY | Estados Unidos | |
dc.relation.ispartofCITY | Hoboken, NJ | |
dc.relation.ispartofTITLE | Alzheimer's & dementia : diagnosis, assessment & disease monitoring. | |
dc.relation.ispartofISSN | 2352-8729 | |
dc.type.snrd | info:ar-repo/semantics/artículo | es_ES |